Biogelx's patented peptide hydrogel technology is currently being used worldwide and can demonstrate these materials successfully mimic the microenvironment of human tissues to grow a wide range of primary and stem cell lines.
These products have applications in fundamental cell research, toxicology/drug development, 3D printing and are translatable to cell therapy/regenerative medicine. The synthetic peptide technology has many benefits including the ability to tune mechanical stiffness and chemical biofunctionality creating a synthetic ECM within an in-vitro environment.
The product's unique cell-matching capabilities provide end-users including academic users, medical researchers and pharmaceutical companies with a realistic alternative to traditional 2D cell culture methods.
Biogelx has been trading for over 8 years, with international customers over 5 continents. Biogelx offices are based in Scotland.